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Abstract
Background: Recently, perfluorooctanoic acid (PFOA) has become a significant issue in many
aspects of environmental ecology, toxicology, pathology and life sciences because it may have
serious effects on the endocrine, immune and nervous systems and can lead to embryonic
deformities and other diseases. Human serum albumin (HSA) is the major protein component of
blood plasma and is called a multifunctional plasma carrier protein because of its ability to bind an
unusually broad spectrum of ligands.
Results: The interaction of PFOA with HSA was investigated in the normal physiological condition
by equilibrium dialysis, fluorospectrometry, isothermal titration calorimetry (ITC) and circular
dichroism (CD). The non-covalent interaction is resulted from hydrogen bond, van der Waals force
and hydrophobic stack. PFOA binding to HSA accorded with two-step binding model with the
saturation binding numbers of PFOA, only 1 in the hydrophobic intracavity of HSA and 12 on the
exposed outer surface. The interaction of PFOA with HSA is spontaneous and results in change of
HSA conformation. The possible binding sites were speculated.
Conclusion: The present work suggested a characterization method for the intermolecular weak
interaction. It is potentially useful for elucidating the toxigenicity of perfluorochemicals when
combined with biomolecular function effect, transmembrane transport, toxicological testing and
the other experiments.
Background
It is well known that the Teflon event involving the
Dupont Company of USA drew serious international
attention to perfluorooctanoic acid (PFOA) [1]; PFOA is
formed from the raw materials used in the production of
Teflon-lined non-stick cooking appliances. Fluoropoly-
mers such as Teflon have very good performances e.g. as
fire retardants and for oil and fat resistance; their byprod-
ucts such as PFOA can be formed by cooking, burning and
environmental degradation. PFOA is still widely used in
basic processes in the aviation, automobile, building
materials, chemicals, electronic, semiconductor and tex-
tile industries. It is persistent and non-biodegradable and
becomes widely distributed in nature, e.g. water [2], bio-
logical bodies [3], human tissues [4] and foods [5]. It can
certainly enter the gastrointestinal tract via the intake of
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foods and water and then it is absorbed and permeates
into the blood and various tissues. Sampling studies have
revealed the presence of PFOA in the bloods of over 90%
of US residents [6]. It may have serious effects on the
endocrine, immune and nervous systems and it can be
delivered to the fetus through the umbilical cord and can
accumulate [7]. It can also cause cancers of the liver, testis,
pancreatic and mammary glands [8], and can lead to
embryonic deformities and other diseases [9,10]. In
recent years, PFOA has become a significant issue in many
aspects of environmental ecology, toxicology, pathology
and life sciences [11,12].
Human serum albumin (HSA) is a major protein compo-
nent of blood plasma but is also found in the interstitial
fluid of body tissues. In mammals, albumin is synthesized
by the liver and has a half-life of 19 days in the circulation
[13]. It is the major contributor to the oncotic pressure of
the blood plasma [14]. It is called a multifunctional
plasma carrier protein because of its ability to bind an
unusually broad spectrum of ligands e.g. inorganic ions,
various drugs, amino acids, fatty acids, etc. Binding to
HSA facilitates their transport throughout the circulation
[15]. Without doubt, interaction of any toxicant with HSA
influences the transport of nutrients and drugs. Recently,
studies have been conducted on the binding of organic
contaminants or toxins to HSA e.g. arazine [16], ochra-
toxin [17], methyl parathion [18] and arsenic [19]. Bind-
ings of PFOA to biomacromolecular such as rat and
Human plasma proteins [20], rat liver-form and kidney-
form alpha 2u-globulins [21], have been investigated at
room temperature. The interaction of organic contami-
nants and HSA is always affected by various environmen-
tal conditions such as pH, strength and temperature [22].
In this work, we investigated the interaction of PFOA with
HSA by equilibrium dialysis, fluorospectrometry, isother-
mal titration calorimetry (ITC) and circular dichroism
(CD) under normal physiological condition, pH 7.40 and
0.15 M electrolyte and 37°C. The object is to analyze the
interaction forces, sites and type and then further under-
stand the toxigenicity of PFOA.
Results and discussion
Equilibrium dialysis of PFOA
The equilibrium dialysis method was used to investigate
the interaction of PFOA with HSA. The PFOA concentra-
tion in the dialysis solution was measured at 37°C at var-
ious dialysis times with no protein in the membrane. The
PFOA dialysis rate approaches 90% at 2 h and exceeds
98% after 4 h (Fig. 1). PFOA passes freely through the
semi-permeable membrane until equilibrium reached.
HSA solution was put into the dialysis membrane as dia-
lysate instead of PFOA, but it was found only in the dial-
ysis bag. Therefore, the equilibrium dialysis is suitable for
investigating the interaction of PFOA with HSA. The dial-
ysis solution was sampled and measured spectrophoto-
metrically to determine the PFOA concentration after
more than 4 h of dialysis.
Characterization of the interactions of PFOA with HSA
The interaction of PFOA with HSA is summarized as fol-
lows:
Both cL0 and cM0 are the initial mole concentrations of
PFOA and HSA, cL is the equilibrium concentration of
PFOA described above. N  is the saturation binding
number of PFOA. The effective fraction (f) of PFOA bound
to HSA and its molar binding ratio (γ) are calculated by
the relations: f = 1-cL/cL0 and γ = fcL0/cM0. The γ value will
approach N with increasing PFOA.
In fact, pH varies widely among normal tissues in the
human body. For example, less than pH 3.0 in gastric
fluid, pH 6.0 in liver and saliva, pH 4.0 – 5.0 on the skin
N
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Equilibrium dialysis of PFOA: (1) – Change of PFOA concen- tration (cL) in the dialysis solution initially containing 9.0 ml of  pH 7.40 BR buffer and 27.0 ml of distilled water, while 3.0 ml  of pH 7.40 BR buffer, 3.0 ml of 5.00 Mm PFOA and 4.0 ml of  distilled water were mixed in the bag at the beginning of the  dialysis Figure 1
Equilibrium dialysis of PFOA: (1) – Change of PFOA 
concentration (cL) in the dialysis solution initially 
containing 9.0 ml of pH 7.40 BR buffer and 27.0 ml of 
distilled water, while 3.0 ml of pH 7.40 BR buffer, 3.0 
ml of 5.00 Mm PFOA and 4.0 ml of distilled water 
were mixed in the bag at the beginning of the dialysis. 
PFOA in the dialysis solution was determined at various dial-
ysis times. (2) – Variation of the PFOA dialysis rate calculated 
by (initial molarity of PFOA in bag – 4cL)/initial molarity of 
PFOA in dialysis membrane, which was used to estimate the 
dialysis equilibrium time.BMC Structural Biology 2009, 9:31 http://www.biomedcentral.com/1472-6807/9/31
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and around pH 7.40 in blood and intestinal tract. Normal
human temperature is 37°C and the electrolyte concen-
tration is between 0.8 and 0.9% (approximately 0.15 M).
In this present work, the experiments were conducted in
0.15 M NaCl at pH 7.40 at 37°C. By measuring a series of
PFOA solutions containing known concentrations of HSA
at pH 7.40, the f and γ values were calculated according to
the above equations. The f decreases linearly with increas-
ing PFOA concentration from curve 1 in Fig. 2, but γ
increases from curve 2. The binding of PFOA approaches
to a constant maximum at 13 when cL0/cM0 is more than
20 from curve 2. The number of amino acid residues pos-
itively charged e.g. Lys, His and Arg is 98 in HSA, which is
no correlation with such an N value. Different from a sul-
fonic azo ligand [23], the PFOA binding to HSA doesn't
results from ion-pair attraction. Strong intermolecular
forces e.g. hydrogen bond, van der Waals forces and
hydrophobic interaction may be involved. The Temkin
isothermal model,   (Ka – adsorption
constant, M-1, ΔQ – saturation adsorption energy, T – the
Kelvin temperature and R – the gas constant, 8.314 J mol-
1K-1) was used to fit the above experimental data. From
curve 3 (Fig. 2), the interaction of PFOA with HSA corre-
sponds to chemical monolayer adsorption. Both ΔQ and
Ka were calculated to be -3.89 kJ/mol and 3.12 × 104 M-1.
The adsorption of PFOA on HSA is exothermic and non-
covalent [24], i.e. no strong bond was formed between
PFOA and HSA.
In order to understand the mechanism of PFOA-HSA
binding, some detailed thermodynamic data are needed.
The ITC measurement may provide information on ther-
modynamic quantities such as enthalpy and heat capacity
changes during the molecular interaction directly from
the heat produced by the reaction, and have been used to
study, for example, protein interactions [25], DNA triplex
formation [26] and HIV protease activity [27]. Fig. 3A
depicts a typical isothermal titration profile obtained by
injecting PFOA into the ITC cell containing HSA. The
resulting values were plotted as a function of cL0/cM0 and
fitted to a two-step sequential binding model by a nonlin-
ear least squares method (Fig. 3B). Values for the equilib-
rium constant (Kb), enthalpy change (ΔH) and entropy
change (ΔS) of the PFOA-HSA reaction were obtained and
γ
N
RT
Q ln Kc aL =−Δ ()
Effect of PFOA (initial concentration from 0 to 1.75 mM in the dialysate) on binding to HSA, initially 0.033 mM Figure 2
Effect of PFOA (initial concentration from 0 to 1.75 mM in the dialysate) on binding to HSA, initially 0.033 
mM. (1) and (2) – f and γ of PFOA; (3) – plots γ/N vs. ln(cL). All the solutions were in 0.15 M NaCl at pH 7.40 at 37°CBMC Structural Biology 2009, 9:31 http://www.biomedcentral.com/1472-6807/9/31
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calculated by the Gibbs free energy (ΔG) equation: ΔG = -
RTlnKb  =  ΔH-TΔ S. The thermodynamic parameters
derived from this curve are summarized in Table 1.
Because both ΔHi values are much less than 60 kcal/mol
[24], the non-covalent binding of PFOA to HSA is con-
firmed.
PFOA is more lipophilic in aqueous solution and it
decreased obviously the aqueous surface intensity. Fifteen
electrophilic F-groups in PFOA can attract strongly the
lone pair electrons of polar side groups of peptide chain,
e.g. FN and FO halogen bonding [28]. HSA is con-
sisted of three homologous all α-helical domains (I–III),
each divided into two subdomains [14]. All the helixic
subdomains are distributed round a hydrophobic intrac-
avity and the hydrophilic side groups of HSA exposed on
the outer surface. In the first step, only one PFOA mole-
cule bound on HSA (Table 1). The f of PFOA is always
more than 90% from curve 1 in Fig. 2 when the cL0/cM0 is
less than 5. Therefore, the first step is complete at approx-
imately 1.5 of cL0/cM0. HSA binding PFOA caused the
entropy decreasing (ΔS1 < 0) in this step. The refolding of
HSA occurred by resuming the released heat. From ΔG1
value, the PFOA-HSA reaction is spontaneous. Moreover,
the higher Kb, 1 value indicated that the binding of the first
PFOA molecule to HSA is firmer. From curve 1 to 9 in Fig.
4, the blue shift of peak emission wavelength from 345 to
335 nm indicated that the static quench of the HSA's
intrinsic fluorescence occurred in the presence of PFOA,
specially obviously when cL0/cM0 is less than 2. Thus, the
first PFOA molecule may bind to the side group of Tyr. As
a result, the deformable linear PFOA may insert into the
hydrophobic intracavity of HSA and bridge between sub-
domains IIA and IIB (No. 1 in Fig. 5) across Trp 213 by
FN and FO halogen bonding with the polar side
groups of Asn, Gln, Asp, Glu, Arg, His, Tyr and Trp and
hydrophobic interaction with the non-polar side groups,
e.g. Val, Leu, Met, Ala and Ile. The first step binding of
PFOA to HSA is similar to that of long chain fatty acids to
HSA [14].
Besides a long carbon chain, PFOA has strong extensibility
on interface of water – particles so that it may spread on
the exposed outer surface of HSA. When cL0/cM0 is more
than 2, PFOA began to bind on the hydrophilic surface of
HSA till a saturation (N2 = 12) via the polar bonds e.g.
ionic interaction, hydrogen bond and FN and FO hal-
ogen bonding (Fig. 3B). By comparison of N obtained by
equilibrium dialysis (Fig. 2) and that (N = N1 + N2 = 13)
obtained by ITC (Fig. 3B), two methods achieves the same
result. From the higher ΔH2 value, the binding sites of
PFOA may bridge between any two helixes all over the
outer surface of HSA (Fig. 5). From ΔG2 value (Table 1),
the PFOA-HSA reaction is spontaneous. In the 2nd step,
the binding of PFOA to HSA caused an obvious entropy
decreasing, i.e. more negative ΔS2 (Table 1), the HSA
structure changed refolding.
By comparison of the emission spectra in Fig. 4, the obvi-
ous blue shift of peak wavelength was found when cL0/cM0
is more than 2. This indicates an obvious change of HSA
conformation, too. As a result, the interaction of PFOA
(A) ITC titration profile of PFOA-HSA binding at pH 7.40 Figure 3
(A) ITC titration profile of PFOA-HSA binding at pH 
7.40. The temperature was 37°C and all the solutions con-
tained 0.15 M NaCl. Each pulse corresponds to a 6.0-μl injec-
tion of 2.50 mM PFOA into the ITC cell (1.4685 ml) 
containing 0.010 mM HSA. (B) The area of each peak in A 
was integrated and corrected for the heat of dilution, which 
was estimated in a separate experiment by injecting the 
PFOA into the buffer.
Table 1: Thermodynamic property of the HSA-PFOA interaction at pH 7.40 at 37°C
i-th step cL0/cM0 Ni Kb, i
(103 M-1)
ΔHi, (kcal/mol) ΔSi
(cal/(mol·K))
ΔGi
(kcal/mol)
1 < 1.5 1 24.7 ± 6.5 -10.0 -12.3 -6.19
2 1.5–20 12 0.55 ± 0.14 -13.8 -32.0 -3.88BMC Structural Biology 2009, 9:31 http://www.biomedcentral.com/1472-6807/9/31
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with HSA is assignable under normal physiological condi-
tion. In addition, the β-pleated sheet content of HSA
decreased obviously and its α-helix increased by 15% in
the presence of PFOA from the change of CD spectra of
HSA (Fig. 6). Thus, the second step in PFOA binding
changed a substantial part of the β-pleated sheet of HSA
into α-helix form. Without doubt, such a binding would
cause a great change of HSA structure and affect the func-
tion of HSA in blood.
Conclusion
The current work investigated the interaction of PFOA
with HSA in the normal physiological acidities of blood
and intestinal tract tissue where PFOA molecules may be
present. The interaction of PFOA with HSA accorded with
the Langmuir isothermal model in two-step sequence, in
which only one PFOA molecule entered the hydrophobic
intracavity in the first step and 12 PFOA molecules bind-
ing on the hydrophilic outer surface in the second step.
The interaction of PFOA and HSA is spontaneous and the
non-covalent bond results in change of HSA conforma-
tion. The possible binding sites were also speculated. The
present work proposed a determination and characteriza-
tion method for the intermolecular weak interaction. If
combined further with the other experiments e.g. biomo-
lecular function effect [29], cell membrane transport of
contaminant [30] and toxicological testing [31], it is more
helpful for elucidating the toxigenicity of perfluorochem-
icals.
Variation of the intrinsic fluorescence of HSA (cM0 = 0.010  mM) with increase of PFOA (cL0 = 0 – 0.300 mM) at pH 7.40 Figure 4
Variation of the intrinsic fluorescence of HSA (cM0 = 
0.010 mM) with increase of PFOA (cL0 = 0 – 0.300 
mM) at pH 7.40. From (1) to (9): cL0/cM0 is 0, 1.0, 1.5, 2.0, 
3.0, 5.0, 10.0, 20.0 and 30.0.
Cartoon illustrating the binding of PFOA to HSA Figure 5
Cartoon illustrating the binding of PFOA to HSA. (1) 
– possible PFOA binding site in the 1st step; from (2) to (13) 
– PFOA binding sites in the 2nd step. Molar ellipiticity curves for HSA (0.010 mM) solutions at pH  7.40 Figure 6
Molar ellipiticity curves for HSA (0.010 mM) solu-
tions at pH 7.40. (1) – no PFOA and (2) – 1.0 mM PFOA.BMC Structural Biology 2009, 9:31 http://www.biomedcentral.com/1472-6807/9/31
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Methods
Instruments and chemicals
Model S-4100 spectrophotometer (Sinco Co., Korea),
which was computer-controlled by Labpro Plus firmware
(Version 060105); Model MSC-ITC system (MicroCal
Inc., USA) with measurement software; Model J-715 CD
Spectropolarimeter (Jasco Instrum., Japan) with second-
ary structure Estimation-Standard Analysis Measurement
software (715/#B014460524, JASCO); Model RC 30 – 5K
semi-permeable membrane (Molecular Weight Cut Off 5
KDa, Shanghai Green Bird STD). Both 0.100 mM HSA
(Sigma) was prepared and stored at 4°C. The other solu-
tions were prepared: a standard PFOA solution (New Jer-
sey, USA) (5.00 mM); Britton-Robinson (BR) buffers (pH
7.40); ECR (1.00 mM, A. R., Sigma) solution; CPC (1.00
mM, purity > 99%, Shanghai Reagents).
Determination of PFOA
A simple and rapid spectrophotometry method for deter-
mining PFOA was developed. The anionic color ligand
eriochrome cyanine R (ECR) and cationic surfactants
cetylpyridinium chloride (CPC) were employed to deter-
mine PFOA. The detailed analytical procedure was
described by [32].
Equilibrium dialysis
Unlike a color ligand [23], PFOA does not absorb visible
light strongly so the interaction cannot be characterized
by VIS spectrophotometry. Therefore, equilibrium dialysis
was used. We designed a new dialysis device (Fig. 7),
where 12.0 ml solutions containing 3.0 ml of BR buffer
(pH 7.40), 0.15 M NaCl, 0.033 mM HSA (cM0), a series of
PFOA concentrations (cL0) and distilled water were mixed
and transferred to dialysis bags (1). A solution (36.0 ml)
containing 0.15 M NaCl, 9.0 ml of BR buffer and distilled
water was added to the dialysis cup (3). The constant tem-
perature (2) of the water bath (4) was kept at 37°C by
adjusting the thermostat magnetic stirrer (5). After 4 h, 1.0
ml of the dialysis solution (3) was collected with the sam-
pling tube (6) and the PFOA concentration (cL) was deter-
mined by spectrophotometry.
ITC measurement
By means of a ITC device, PFOA solution (2.50 mM in pH
7.40 BR buffer) was injected about 40 times in 6-μl incre-
ments at 3-min intervals into an isothermal cell contain-
ing HSA (10.0 μM in pH 7.40 BR buffer). The cell
temperature was maintained at 37°C and all the solutions
contained 0.15 M NaCl. Heats of dilution of PFOA,
obtained separately by injecting into the buffer, were used
to correct the data. The corrected heats were divided by the
number of moles injected and analyzed using the Origin
software (version 7.0).
CD measurement
BR buffer (1.0 ml, pH 7.40) was mixed with 0.010 mM
HSA in three flasks; or 1.00 mM PFOA was added and the
solutions were diluted to 10.0 ml with distilled water.
Simultaneously, a reagent blank without PFOA was pre-
pared. Before measurement, all the solutions were diluted
from 0.1 to 10.0 ml with 10% BR buffer. Each sample was
allowed to equilibrate for 15 min, then injected into a 0.1-
cm light path cell, and the mean residue ellipticity (MRE)
of HSA was measured between 195 and 250 nm by spec-
tropolarimetry.
The new dialyzer was designed as illustrated: (1) – semi-per- meable membrane with 15.0 ml of retentate; (2) – the tem- perature sensor for maintaining the reaction at constant  37°C (3) – Dialysis solution less than 50.0 ml; (4) – water  bath at constant 37°C Figure 7
The new dialyzer was designed as illustrated: (1) – 
semi-permeable membrane with 15.0 ml of reten-
tate; (2) – the temperature sensor for maintaining 
the reaction at constant 37°C (3) – Dialysis solution 
less than 50.0 ml; (4) – water bath at constant 37°C. 
The apparatus was placed on a thermostated magnetic stir-
rer (5) and rotary magnets were used to mix solutions 3 and 
4 thoroughly. The PFOA concentration in solution (3) was 
determined from the sampling tube (6).BMC Structural Biology 2009, 9:31 http://www.biomedcentral.com/1472-6807/9/31
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